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ABSTRACT: The clinical implantation of gene therapy is
hindered by the limitations of current gene delivery vectors,
namely, safety issues regarding viral vectors and low
transfection efficacy regarding nonviral vectors. Thus, the
design of safe and efficient gene carriers is a key point for the
success of such therapies. In addition, when employing
genetically modified cells for further applications, the selection
of successfully modified cells becomes crucial. To address
these issues, we have developed multicomponent nano-
particles composed of poly(ß-amino ester) (pBAE) polymers,
plasmid DNA, and superparamagnetic iron oxide nano-
particles (SPIONs). Whereas pBAEs were initially employed
as safe and biocompatible carriers with improved transfection
efficiency, as compared to commercial vectors, SPIONs were used because of their magnetic character that enables cell
selection. Surprisingly, the results presented here revealed an unexpected enhancer effect of SPIONs on the transfection
efficiency of pBAE/pDNA polyplexes in both permissive and reluctant to transfection cell lines. This unanticipated outcome,
together with the allowance to perform a selective magnetic sorting of genetically modified cells without interfering in cell
transfection, opens the door to SPION-containing nanoparticles as promising tools for cell therapy approaches.
■ INTRODUCTION
Gene therapy emerged as a pioneering technique to treat or
improve the health condition of patients by modifying their cells
genetically. Although it aroused huge expectations, the number
of gene therapeutic products in the market is limited and does
not correlate with numerous lab-scale research studies. The
major historical problem is the development of efficient and safe
systems for the delivery of therapeutic genes into the target cells.
Depending on their origin, gene delivery vectors can be divided
into two types: viral and nonviral. Viral vectors have naturally
evolved to infect cells with high efficiency. However, they imply
some important drawbacks, safety concerns being the main issue
to circumvent. In addition, they have limited packaging capacity
and have an expensive large-scale production.1−3 Furthermore,
viral vectors often show poor tissue and organ target-specificity
and are susceptible to neutralization by serum antibodies and the
complement system.4−6 On the contrary, nonviral gene carriers,
although showing lower transfection efficiency when compared
to viruses, have become an alternative of great interest in the last
few decades as they offer many relevant advantages. These
systems not only overcome major viral delivery toxicity
problems but also have other worthwhile properties including
in vivo stability, low-cost production, facility to scale up their
production, and the ease of synthesis and modification.7−10 The
most widely used nonviral systems are complexes formed by the
electrostatic interaction of nucleic acids with cationic lipids
(lipoplexes) and/or cationic polymers (polyplexes). The latter
are advantageous in terms of versatility in their design, large
DNA cargo capacity, the possibility of being rationally
synthesized incorporating functional groups with relative ease
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and flexibility, and the ability to more efficiently condense DNA
than lipoplexes.11 In the last few years, polyplexes encapsulating
DNA or RNA have gained importance in this field due to their
lower liver accumulation rates when used for in vivo
applications.12,13 However, their fairly low transfection
efficiency remained a major drawback.14 For this reason, in
the last few years, researchers devoted many efforts to improve
their transfection efficiency employing different strategies.15,16
Recently, a class of cationic, biodegradable polymers known as
poly(β-amino ester)s (pBAEs) has been developed as promising
nucleic acid delivery systems.17,18 These polymers possess a high
transfection efficacy in vitro and in vivo, together with low
toxicity and the ability for ligand-specific uptake. Their capacity
to efficiently complex nucleic acids into discrete nanoparticles
and transfer genetic material to target cells makes them suitable
as gene delivery vectors for cell therapy applications.19
Furthermore, our group has developed a family of poly(ß-
amino ester) polymers with oligopeptide-modified termini
(OM-pBAEs) that proved increased transfection efficiency in
cell-type-specific manner and excellent biocompatibility. These
previous results have demonstrated that tailored formulations of
different cationic OM-pBAE polymers are capable of rendering
nanoparticles with specific features, such as cell specificity or
intracellular localization.20 More recently, our group has
expanded the use of this oligopeptide end-modification through
the use of mixtures of both cationic and anionic OM-pBAE
polymers as delivery systems for siRNA, leading to a simple
method to tailor the surface charge of the resulting nano-
particles, while maintaining their ability tomediate efficient gene
silencing.21 Finally, it has been reported the possibility of tuning
the hydrophilicity−hydrophobicity ratio of pBAE formulations
to obtain particles with higher siRNA packaging capacity and
increased stability.22 All these advantageous characteristics,
especially their high transfection efficiency and their safety
profile, confer OM-pBAEs a high suitability as gene delivery
vectors.
Genetically modified cells can next be employed for several
further purposes including immunotherapy, stable transgene
expression in eukaryotic cells, theranostics, ex vivo models for
clinical applications, and cell therapy strategies.23−30 Most of
these applications, specially the ones related to cell therapy,
require a selection of successfully modified cells to increase the
probabilities of achieving a final beneficial effect, and, therefore,
the enrichment and selection of genetically modified cells
become a key matter.31 At this point, and given the current
growing interest in the combination of both gene and cell
therapy strategies, a system allowing simultaneously the genetic
modification of cells and their later selection for in vivo
implantation would be of great interest.
Cell therapy is an emerging approach showing promising
results in many fields such as bone marrow transplants, diabetes
mellitus treatment,30 cardiovascular disease,32 bone engineer-
ing,33 and the treatment of articular cartilage lesions (focal
defects, osteoarthritis).34 This procedure relies on replacing
damaged or dysfunctional cells or tissues with healthy,
functioning ones. The cells used for cell therapy applications
are usually stem cells obtained from the same patient
(autologous) or from a compatible donor (allogeneic) to repair
the damaged tissue. In addition, the possibility to genetically
modify these therapeutic cells has opened a door toward the
development of new therapies applied not only to tissue
regeneration, but also to many genetic diseases, including blood
cell diseases such as hemophilia and cancer.29 In these cases,
genetically modified cells are often administered to patients with
therapeutic purposes. These strategies imply as main hindrance
the susceptibility of therapeutic (stem) cells to be used by the
tumors to promote their own growth due to their capacity to
differentiate into other cell types.35 Therefore, using them
requires the selection of modified cells to ensure that only the
therapeutic ones are delivered to patients, thus increasing the
probabilities of the therapy to success and decreasing side
effects.
The two most common ways to perform cell sorting are based
either on fluorescence or on magnetism. Magnetic labeling is
frequently easier, cheaper, and quicker than dying or modifying
cells to express a fluorescent protein.36,37 Moreover, if polymers
are fluorescently labeled (modified), they will differ from the
original ones and consequently end in regulatory hurdles.
Besides, for further clinical applications, which always imply
scale-up processes, these advantages become even more
relevant. For these reasons, in this work, a magnetic cell sorting
was proposed, specifically, using superparamagnetic iron oxide
nanoparticles (SPIONs), a type of magnetic nanoparticles
(MNPs). They were selected because they have been used, to
date, as (a) contrast agents for magnetic resonance imaging and
magnetic-cell-labeled tracking in diagnostic applications38−40
and (b) for magnetofection, which is a transfection technique
that uses magnetic fields to attract particles containing magnetic
nanoparticles into cells.41−43 The strategy proposed here is the
use of SPIONs to select the transfected cells taking advantage of
their magnetic feature and with the ambition of achieving higher
transfection efficiencies through magnetic cell sorting. The
proof-of-concept detailed hereafter could be of great interest for
further use in stem cells for cell therapy strategies.
We plan to overcome two of the main challenges previously
described, namely, (1) obtain high levels of gene transfection in
a safe manner and (2) separate the genetically modified cells
from the ones that do not carry the therapeutic gene using a
novel multicomponent nonviral gene delivery vector. The new
SPION-containing nanoparticles will be characterized by
different physicochemical techniques. The expression of the
reporter gene green fluorescent protein (GFP) will be used to
evaluate the transfection efficiency of these novel SPION-
containing nanoparticles and to compare this parameter
between the nanoparticles with and without SPIONs. These
tests will be performed using different in vitro cell cultures,
ranging from a permissive cell line to a highly difficult-to-
transfect one. Additionally, a sorter of transfected cells will be
performed exploiting the magnetic feature of SPIONs to
positively select and, therefore, enrich the fraction of transfected
cells.
To sum up, the approach presented in this work is based on
the combination of polyplexes, formed by plasmid DNA and
OM-pBAEs, together with SPIONs. The specific structure and
composition of the resulting nanoparticles will allow not only
the separation of the genetic modified cells from the ones that do
not contain the foreign DNA by applying an external magnetic
field, but also an unexpected enhancement on cell transfection.
■ RESULTS AND DISCUSSION
Manufacturing of SPION-Containing Nanoparticles. In
the present work, 2,3-dimercaptosuccinic acid (DMSA)-coated
SPIONs44,45 were employed. These SPIONs have been proven
to have excellent properties in terms of efficiency and
biocompatibility for application to target cancer cells such as
MCF-7 breast cancer cells46 and have been already used for
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nanothermometry, magnetic separation, and bioremediation.47
Considering that such SPIONs are biocompatible and have been
already used in biomedical applications, their use as gene
delivery transfection agents has been proposed. It is worth
noting that although the safety of SPIONs’ characterization is
simple in the current article, SPIONs are approved by the FDA
and EMA to be used in humans, so their safety profile has been
described earlier.
First, different strategies to form nanoparticles containing
both pDNA and SPIONs to transfect a variety of cell lines have
been explored, aiming at determining whether SPION-
containing pBAE nanoparticles are able to enhance the
efficiency of transfection from that of pDNA/pBAE polyplexes.
Considering that pDNA can be encapsulated by means of
cationic pBAEs20 and once we proved that SPIONs can be
encapsulated as well (see Figure S1, Supporting Information),
we explored different ways to form DNA-loaded SPION-
containing nanocarriers. In particular, the three types of
nanoparticles explained in the Materials section were formed
and tested: (a) nanoparticles where the SPIONs and DNA were
encapsulated by the polymer, named “T” (together); (b)
nanoparticles where the DNA was encapsulated by the polymer
and then SPIONs were added to the solution, named “S”
(separated); (c) multicoating nanoparticles consisting of four
layers: a nucleus formed by SPIONs, a polymer layer
encapsulating this nucleus, a plasmid DNA layer, and another
polymer layer to ensure the DNA encapsulation, named “M”
(Figure 1A).
T type of SPION-containing nanoparticles was formed
following the most similar procedure to the SPION-free
nanoparticles (NP without SP). First, a gel retardation assay
confirmed the complexation of the plasmid with the pBAE
polymer, without and with the presence of SPIONs (Figure 1B).
As shown in Figure 1C, these nanoparticles showed a bigger
hydrodynamic diameter than nanoparticles without SPIONs
(NP wo SP) but in the acceptable size range and a positive
surface potential. S-type nanoparticles are equally formed as the
NPs with the exception that just when they precipitate, SPIONs
are added to the solution. Thus, SPIONs are thought to be
attached to the nanoparticle surface. These NPs showed almost
the same size and ζ-potential as nanoparticles without SP (NP
wo SP). Although it could be expected a negative surface charge
due to the hypothesized presence of the SPIONs at the external
part of the nanoparticle, these nanoparticles remain cationic
because we did not add enough SPIONs to form a continuous
layer surrounding the whole nanoparticle surface. This was
made to maintain the cationic character of the nanoparticles,
required to enhance cell transfection. Finally, M-type SPION-
containing NPs are the most differently formed from conven-
tional DNA/pBAE NPs as they imply a layer-by-layer (LbL)
deposition of the different elements. The LbL deposition of
oppositely charged polyelectrolytes on the surface of condensed
DNA or viral particles has been largely employed.48−50
However, LbL on the surface of inorganic nanoparticles, such
as the SPIONs employed here or the gold nanoparticles, has
recently attracted attention from researchers because of their
capability to deliver therapeutic genes to human cells.24 Higher
hydrodynamic diameter and PDI (Figure 1C,D) of these
particles were expected because of the LbL procedure.51,52
Evidence of the LbL deposition could be observed analyzing
the ζ-potential of multicoating nanoparticles of C32-CR3/
pBAE at a weight ratio of 50:1 with the pGFP and at a SPION
Figure 1. Manufacturing and characterization of SPION-containing nanoparticles. (A) Scheme of the different structures hypothesized for SPION-
containing nanoparticles (T = together nanoparticles; S = separate nanoparticles; and M = multicoating nanoparticles); (B) electrophoretic mobility
shift assay (EMSA) of naked pGFP (pGFP) and the plasmid complexes with only pBAE (NP) and with pBAE + SPIONs, at the indicated
concentrations, with the different types of structures (T, S, or M); (C) hydrodynamic diameter (in nm) and ζ-potential (in mV), by dynamic light
scattering (DLS) analysis, of nanoparticles without SPIONs and different SPION-containing nanoparticles at a fixed SPIONs’ concentration; (D)
polydispersity index (PDI) of the same nanoparticles; and (E) layer-by-layer (LbL) ζ-potential analysis of M-type SPION-containing nanoparticles.
All data correspond to mean ± standard deviation (SD) values of, at least, three replicates.
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concentration of 5 μg mL−1 (Figure 1E). As previously
mentioned, a nucleus of SPIONs, which are negatively charged
due to its DMSA coating, was covered with an initial layer of
polymer, which was positively charged, inducing a drastic
change of the ζ-potential of the nanoparticles formed, from
clearly negative to positive values. Subsequent addition of DNA
produced a change of the ζ-potential from positive to negative,
thus demonstrating that it was interacting with the positive
nanoparticles previously formed. Similarly, further additions of
either polymer or DNA layers switched the ζ-potential of the
polyplexes. The plot on Figure 1E shows the ζ-potential switches
derived from three polymer layers. However, because of their
excessive size (see Figure S2, Supporting Information), M
nanoparticles with three polymeric layers were not employed.
Further experiments were carried out with two polymer layers of
M-type nanoparticles, which are formed by a total of four layers
including the SPION nucleus, the two polymeric layers, and the
DNA layer.
SPIONs’ Optimal Concentration for Transfection
Assays. Once these three approaches to form SPION-
containing nanoparticles were characterized in terms of size
and polydispersity, their transfection efficiency was next
analyzed. We first determined the optimal SPION concen-
trations to work with and then which type of SPION-containing
nanoparticles should be chosen for further experiments.
First, cell viability was determined by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays on differ-
ent cell cultures exposed to different SPION concentrations to
assure that the internalization of SPIONs did not negatively
impact cellular metabolism. As shown in Figure 2A, at
concentrations up to 75 μg of SPIONs mL−1, Cos-7 cells
showed no signs of toxicity, and for HeLa cells, the tolerance
raised up to 100 μg of SPIONs mL−1 (see Figure S3, Supporting
Information). This is in accordance with previous studies that
report that some toxicity may be observed when concentrations
of SPIONs exceed 100 μg mL−1 depending on the cell type.53
Then, a screening of different SPION concentrations into
DNA/pBAE polyplexes was conducted with the aim to choose
the ones showing more transfection efficiency. Considering the
cell compatibility results obtained with the SPIONs (Figure 2A),
a range between 0 and 20 μg of SPIONs mL−1 was chosen. This
experiment was performed with Cos-7 cells since they are
considered a permissive cell line and with one common type of
nanoparticles (T-type) for all the SPION concentrations. The
other types of SPION-containing nanoparticles would be later
deeply analyzed in terms of transfection efficiency. In parallel,
viability of Cos-7 cells was also assessed when incubated with
SPION-containing nanoparticles (specifically T-type) (Figure
2C). In this case, the results show that SPIONs’ compatibility is
enhanced probably due to their encapsulation inside the pBAE
Figure 2. SPION cellular screenings. (A) MTT assay on Cos-7 cells to determine their tolerance to SPION concentration (SP); (B) fluorescence-
activated cell sorting (FACS) analysis regarding the transfection efficiency screening of different SPION concentrations into C32-CR3/pGFP (50:1)
T nanoparticles; and (C)MTT assay on Cos-7 cells to determine their tolerance to C32-CR3/pGFP (50:1) T nanoparticles. Results correspond to at
least three replicates performed in a single experiment. t-Test was applied in this experiment to find out significant differences. C+ = Lipofectamine
transfection reagent; C− = cells incubated with only media.
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polymers, which were already demonstrated to be nontoxic at
these concentrations.54,55
The expression of the reporter gene GFP was used to evaluate
the transfection efficiency. Before quantifying GFP expression
by flow cytometry, micrographs of the different conditions were
taken to be able to compare qualitatively the transfection
efficiency of each formulation tested (see Figure S4, Supporting
Information). The results observed through fluorescence
microscopy were quantitatively corroborated by FACS analysis,
as shown in Figure 2B. Remarkably, this figure indicates that at a
SPION concentration ranging between 2 and 10 μg mL−1, the
transfection efficiency significantly increased in comparison to
nanoparticles that do not contain SPIONs (NPs), indicating
that probably below 2 μg of SPIONs mL−1, the amount of these
magnetic nanoparticles might not be enough to cause any effect
on the cells. On the other hand, at concentrations higher than 10
μg of SPIONsmL−1, these magnetic nanoparticles (MNPs) may
agglomerate, leading to inefficient uptake of polyplexes. This
plot also reveals that the highest percentage of transfected cells
was observed around 5 μg mL−1 of SPIONs. From
concentrations higher than 5 μg SPIONs mL−1, transfection
ratios decreased. Thereby, 0.5, 2.5, and 5 μg of SPIONs mL−1
were the chosen concentrations to work with in further
experiments. Interestingly, these working concentrations are
far from the toxicity range of SPIONs showed in Figure 2A.
Transfection Screening of the Different SPION-
Containing Nanoparticles. Once the SPION concentrations
were established, the most efficient type of nanoparticle had to
be chosen. To do so, Cos-7 cells were treated with the three
types of nanoparticles formed at 0.5, 2.5, and 5 μg of SPIONs
mL−1. The transfection efficiencies of all the different conditions
were first observed by fluorescence microscopy (Figure 3A) and
then quantified by FACS (Figure 3B).
Given the results showed in Figure 3, S nanoparticles were
chosen over T NPs because of their higher transfection
efficiency at the two highest concentrations of SPIONs as
compared to T nanoparticles. In addition, S nanoparticles’
results showed lower variability than the ones from T NPs.
Moreover, the presence of SPIONs not only improved cell
transfection at the two highest concentrations, but also
significantly enhanced cell transfection efficiency of S nano-
particles at all the concentrations tested as compared to
nonloaded NPs. Therefore, in further cell transfections, this
type of nanoparticles was selected.
On the other hand, despite not showing significant differences
with NPs in two of the three concentrations of SPIONs tested,
M nanoparticles were also chosen for further in vitro studies
because of their singularity in their LbL structure. In many
applications, this kind of structures could be very useful for the
possibility to load different types of active principles in the
different layers of the complex.
Cell Uptake Differences between SPIONs and SPION-
Containing Nanoparticles. Once it was proven that the
addition of SPIONs to the pBAE/DNA nanocarriers enhanced
their cell transfection efficiency, and the optimal SPION
concentration to work with was established, we aimed to
demonstrate that a multicomponent nanoparticle comprising
SPIONs, pBAE, and DNA would be more efficient in terms of
cellular uptake than the bare SPIONs, which have been broadly
employed as gene delivery systems complexing biological
molecules such as antibodies, peptides, hormones, or drugs to
their surface.56,57 To this end, the iron content of HeLa cells
treated with bare SPIONs and with SPION-containing S-type
NPs was quantified 48 h after transfection.
Given that cells have a basal level of intracellular iron content,
the obtained results were normalized so that only the excess of
iron due to the presence of internalized magnetic nanoparticles
is plotted. As it can be observed in Figure 4, cells treated with
bare SPIONs (naked) at 2.5 μg of SPIONs mL−1 internalized
4.91 ± 2.02 pg of Fe/cell more than untreated cells, whereas
those treated with bare SPIONs at 5 μg mL−1 had a difference of
8.12 ± 1.12 pg of Fe/cell. On the other hand, C32-CR3/pGFP
(50:1) S nanoparticles prepared at 2.5 μg of SPIONs mL−1 had
7.03 ± 1.25 pg of Fe/cell more than control cells, whereas those
treated with the same nanoparticles prepared at 5 μg of SPIONs
mL−1 internalized 14.98± 2.25 pg of Fe/cell more. These results
were in accordance with what was expected since the more the
Figure 3. Transfection screenings of the different nanoparticles. (A)
Fluorescence microscopy images (I): 0.5 T; (II): 0.5 S; (III): 0.5 M;
(IV): 2.5 T; (V): 2.5 S; (VI): 2.5 M; (VII): 5 T; (VIII): 5 S; (IX): 5 M;
(X) NPs without SPIONs; (XI): positive control of Lipofectamine;
(XII): negative control of untreated cells and (B) FACS analyses of the
T, S, and M C32-CR3/pGFP (50:1) nanoparticles’ transfection on
Cos-7 cells at different SPION concentrations. Results correspond to
mean ± SD values of at least three replicates. A t-test was performed
here to find out significant differences. T = together nanoparticles; S =
separate nanoparticles; M = multicoating nanoparticles; C+ =
Lipofectamine transfection reagent; C− = cells incubated with only
media.
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SPIONs were provided to the cells, the more the iron was
internalized. In addition, several other studies have reported a
range of 10−25 pg of Fe/cell in HeLa cells (the same employed
here) when SPIONs were used with a transfection agent.58−60
It is worth remarking the complementarity of ICP results with
those of uptake and transfection experiments. Altogether, with
these results, we are able to demonstrate that the three
components of the complexes designed are efficiently
internalized in cells: first, polymer uptake, although not studied,
must take place to enable pGFP transfection, which is
demonstrated in Figure 3. Finally, with ICP experiments, we
also demonstrate that, at the same time, SPIONs are internalized
even more efficiently if they are complexed with our nano-
particles.
The fact that the cells treated with complexed SPIONs
showed more iron content compared to those treated with bare
SPIONs at both SPION concentrations tested is, at first sight,
surprising. We could hypothesize the following: since the
coating of 2,3-dimercaptosuccinic acid (DMSA) causes SPIONs
to be negatively charged, they may experiment repulsion with
cell membranes. Thus, although it is not yet clear, it has been
reported that the mechanism of cellular uptake of DMSA-
SPIONs may be related to endocytosis.61 Moreover, such cell
uptake pathways are susceptible to saturation. Therefore, it is
most probable that a high concentration of free SPIONs (in the
naked sample) will saturate the route of entry, and this may lead
to a high number of SPIONs to remain in the extracellular
media. In other words, when one single SPION-containing NP
enters a cell, several SPIONs attached to the pBAE will enter at
once. By contrast, the bare SPIONs have to be internalized one
at a time by each cell receptor.
To sum up, these results indicate that more intracellular iron is
obtained for a fixed concentration of SPIONs when these
magnetic nanoparticles are complexed with pBAE and pDNA as
compared to when SPIONs are internalized alone. Thus, in
terms of cell uptake, the gene delivery system consisting of a
multicomponent nanoparticle is more efficient than naked
SPIONs. Besides that, results obtained so far suggest that
SPIONs improve transfection. To confirm this unanticipated
but desirable effect, more experiments were performed.
SPIONs Improve Cell Transfection of pBAE/pDNA
Polyplexes. Experiments detailed above suggested a positive
effect of SPIONs on cell transfection. To confirm it, transfection
efficiencies of S and M nanoparticles, prepared at 0.5, 2.5, and 5
μg of SPIONs mL−1, were studied in three different cell lines
(Cos-7, HeLa, and U-87 MG). In particular, the expression of
the reporter gene GFP was analyzed by fluorescence microscopy
(see Figures S5−S10, Supporting Information) and through
flow cytometry analysis. These experiments were performed
using two different polymers: C32-CR3, abbreviated as C32-R;
and C6-CR3, named C6-R. The latter was used because of its
capability to form more stable nanoparticles due to its
hydrophobic moiety,22 able to be lyophilized without changing
their physicochemical properties.55 The balance between
stability of the polyplexes and cytotoxicity would determine
the best performing polymer for each cell line.
As mentioned before, Cos-7 is considered as quite permissive
to the transfection cell line. For this reason, these were the cells
employed for preliminary experiments and the first ones to test
the effect of SPIONs on cell transfection. Then, cells from a
cervical cancer (HeLa), which are more difficult to transfect,21
were analyzed. Finally, the glioblastoma cell line U-87 MG was
employed as a model of cells that are highly difficult to modify
using nonviral vectors.62
As previously shown, SPIONs remarkably increased the
transfection efficiency of C32-CR3 polyplexes in Cos-7 cells
(Figures 2B and 5A). The transfection efficiency of these
polyplexes was almost doubled when 2.5 or 5 μg of SPIONs
mL−1 was added to the NPs, and for any of the three SPION
concentrations tested, it was higher than when using NPs. No
significant differences were observed between the two highest
concentrations of SPIONs or between S and M nanoparticles.
On the other hand, we also tested the C6-CR3 polymer. This
polymer is very similar to C32, although due to modifications on
its lateral chains, it is more hydrophobic (see chemical structure
below, in Figure 7). This small change did not induce changes in
the physicochemical properties of nanoparticles (data not
shown). In the case of C6-CR3-based polyplexes (Figure 5D),
differences were observed between the types of nanoparticles
used: not all the nanoparticles tested increased the transfection
efficiency of the nanoparticles without SPIONs. This only
happened with 2.5 and 5 μg of SPIONsmL−1 for S nanoparticles
and 5 μg of SPIONs mL−1 for M ones. Therefore, for C6-CR3-
based polyplexes, 5 μg of SPIONs mL−1 was the optimal
concentration of the three evaluated, and S NPs were the best
type of nanoparticles. Since both concentrations showed similar
results, we selected the one with the higher SPION loading to
facilitate magnetic sorting in future experiments.
Regarding HeLa cells (Figure 5B,E), the transfection
efficiency of C32-CR3 polyplexes was remarkably increased
when 2.5 or 5 μg of SPIONs mL−1 was added to the S
nanoparticles or when 5 μg of SPIONsmL−1 was added to theM
ones. At this SPION concentration, S and M showed the same
transfection efficiency, and at lower concentrations, the
transfection was higher in S ones. In the case of C6-CR3
polyplexes, the transfection efficiency was only clearly increased
with the S NPs at 5 μg of SPIONs mL−1 (Figure 5E).
Finally, the percentages of GFP expression of U-87 MG cells
gave evidence of their reluctance to transfection (Figure 5C,F).
However, the transfection efficiency of C32-CR3-based
polyplexes on these cells was significantly enhanced by the
presence of SPIONs at their highest concentration (5 μg mL−1)
on M nanoparticles and at any of the concentrations tested for S
Figure 4. Inductively coupled plasma-optical emission spectrometry
(ICP-OES): cellular iron content analysis of nanoparticles. Untreated
cells’ iron content was normalized to 0 pg of Fe/cell. Results correspond
to mean± SD of at least triplicates. Analysis of variance (ANOVA) was
applied to find out statistical differences.
ACS Omega Article
DOI: 10.1021/acsomega.8b02905
ACS Omega 2019, 4, 2728−2740
2733
nanoparticles. The optimal SPION concentration was clearly 5
μg mL−1, and at this concentration, S and M nanoparticles
showed 3-fold enhanced transfection efficiency. The trans-
fection efficiency of C6-CR3-based polyplexes without SPIONs
(NP) was higher than that of C32-CR3 ones on U-87 MG cells.
Regarding SPIONs, they had a positive effect on transfection
efficiency on these cells for any concentration and any type of
C6-CR3-based SPION-containing nanoparticles tested. Inter-
estingly, S nanoparticles with 5 μg of SPIONs mL−1 showed the
best result, doubling the transfection efficiency of NP. In
conclusion, SPIONs show a clear enhancer effect on the
transfection of U-87 MG cells.
The fact that in the three cell lines tested, C6-CR3 polyplexes
without SPIONs (NPs) showed higher or at least the same
transfection efficiencies as C32-CR3s was not surprising. Also,
C6-based polyplexes in general needed higher amounts of
SPIONs to show significantly increased transfection efficacy. It
has been discussed that although not all the combinations
between DNA, pBAEs, and SPIONs tested were able to
significantly enhance cellular transfection, the clear majority of
them did show higher transfection efficiency than the same NPs
only combining pBAEwith DNA (NP). This assertion applies to
the two types of nanoparticles tested (S andM), although better
results were obtained with the S ones. Thereby, the transfection
efficiency enhancer effect of SPIONs in Cos-7, HeLa, and U-87
MG cell lines was clearly proven.
Taking an overview of the three cell lines tested, it is possible
to assert that in the case of a permissive cell line as Cos-7, the
best performing SPION-containing nanoparticle tested (C32
5S) can duplicate the transfection capability of C32-CR3-NP.
However, in cells that are more difficult to transfect, such as U-
87 MG or HeLa, which show a transfection efficiency of around
10%when using NPs without SPIONs, the effect of the presence
of SPIONs in the polyplexes can achieve 3-fold higher values of
transfection efficiency. Thereby, although the absolute values of
transfection on such cell lines aremuch lower than in Cos-7 cells,
the increase in cell transfection efficiency due to the presence of
SPIONs is higher. These are encouraging results regarding cell
Figure 5. Transfection efficiency results of S- and M-type C32-CR3/pGFP (50:1) (A−C) and C6-CR3/pGFP (25:1) (D, E) SPION-containing
nanoparticles into Cos-7 (A and D), HeLa (B and E), and U-87 MG cells (C and F). Values correspond to the mean ± SD of triplicates of the same
experiment. A t-test was applied to find out statistical differences. S = separate nanoparticles; M = multicoating nanoparticles; C+ = Lipofectamine
transfection reagent; C− = cells incubated with only media. Scale bars are different depending on cell line to facilitate the reading.
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therapy strategies since the cells that are used for these purposes
usually show high reluctance to genetic modification.
It is worth remarking that transfection efficiency could be even
improved by adding a magnetic field when performing the
transfection to facilitate the movement of the SPIONs.
However, in the present study it was not used since the capacity
of the whole complexes to transfect cells was the factor to study,
without external forces, with the aim to compare with particles
without SPION loading.
Magnetic Cell Sorting. As mentioned before, the second
major point of the present work is to select those genetically
modified cells benefiting from the magnetism of SPION-
containing NPs. To do so, magnetic columns were used due to
their ability to recover themagnetic fraction, ease of preparation,
capacity to work with high number of cells, and allowance of a
rapid and efficient cell separation. The first parameter evaluated
was the expression of GFP before performing the sorting and in
both fractions (magnetic and nonmagnetic) obtained after the
sorting (Figure 6A).
As Figure 6A shows, S nanoparticles, as well as the M ones,
showed significantly increased levels of GFP expression on their
magnetic fractions as compared to the nonsorted samples.
Accordingly, the eluted or nonmagnetic fraction showed lower
transfection efficiency. By contrast, negative and positive
controls and NP (samples without SPIONs) maintained their
GFP expression levels in both sorted and nonsorted cells, thus
demonstrating that sorting does not negatively affect cell
transfection.
Next, the magnetic labeling of cells was evaluated. To do so,
the number of cells was normalized between the magnetic and
the nonmagnetic fraction of the different conditions, and the
percentage of each fraction was plotted (see Figure S11,
Supporting Information). Once the transfection efficiency and
the magnetic labeling were analyzed, we next evaluated what
percentage from the total number of cells did represent every
category (Figure 6B), namely, (a) cells expressing GFP and
magnetically labeled (GFP + SP+); (b) cells expressing GFP but
not magnetically labeled (GFP + SP−); (c) cells not expressing
GFP but magnetically labeled (GFP − SP+); and (d) cells that
neither express GFP nor were magnetic (GFP − SP−). The first
fraction (GFP + SP+) would contain the desired cells, being both
magnetic (have internalized SPIONs) and genetically modified
(express GFP coded by the pDNA). For further clinical
applications, enriching this fraction might be very important
to ensure that all the cells reimplanted in a patient are carrying
the therapeutic gene and therefore increase the probability of
success of the therapy. Collecting these four fractions from the
total number of cells allowed us to discard false-positive and
-negative events.
Figure 6B shows that the fraction of cells expressing GFP and
being magnetically labeled (GFP + SP+) represented almost
80% in the case of cells treated with S nanoparticles. Cells treated
with M nanoparticles showed around 60% of this “desired
fraction”, where both transfection and magnetic labeling had
occurred. These results confirm the usability of our system. On
the other hand, the fraction of cells that were magnetic but not
transfected (GFP − SP+) represents the false-positive events.
Since previous studies report that in cell therapy applications
stem cells could favor tumor self-growth in vivo,63 the
percentage of cells in this fraction should be reduced. To this
purpose, an appealing strategy could be the covalent attachment
of the magnetic nanoparticles to the polymer.
On the other hand, as shown in Figure 6B, the nonmagnetic
fraction of samples without SPIONs (NPs, C+, and C−)
represented most of the cells. In the case of NP and C+, these
nonmagnetic cells were distributed between the GFP+ and the
GFP− fraction, according to their transfection efficiency,
whereas in the case of C−, the cells were GFP− in large majority.
To sum up, this magnetic sorting has allowed the massive
separation of each sample into four fractions according to
transfection efficiency and magnetic labeling of cells, showing
promising results.
Overall, the obtained results have revealed the enhancer effect
of SPIONs on the transfection of both permissive and reluctant
to transfection cell lines. Furthermore, the presence of SPIONs
in the polyplexes allowed not only such unexpected increase of
cell transfection but also the selective magnetic separation of
genetically modified cells. The enrichment of the transfected cell
fraction might be crucial for further clinical cell therapy
applications, and therefore the results presented here open the
door to SPION-containing nanoparticles as promising tools for
stem cell-based therapies.
■ EXPERIMENTAL SECTION
Materials. Reagents and solvents used for synthesis were
purchased from Sigma-Aldrich. Plasmid pmaxGFP (3486 bp)
Figure 6. Magnetic cell sorting. FACS analysis regarding (A) the
transfection efficiencies of C6-CR3 S and M nanoparticles on both
magnetically sorted and nonsorted HeLa cells and (B) each fraction of
sorted HeLa cells treated with S and M nanoparticles. Results are
presented as mean ± SD of triplicates. S = separate nanoparticles; M =
multicoating nanoparticles; C+ = Lipofectamine transfection reagent;
C− = cells incubated with only media.
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was obtained from Amaxa. CR3 (NH2−Cys−Arg−Arg−Arg−
COOH) and CD3 (NH2−Cys−Asp−Asp−Asp−COOH)
peptides were obtained from GL Biochem Ltd (Shangai) and
transferred to hydrochloride salt form before use. DMSA-coated
SPIONs (hydrodynamic size = 45 nm; surface charge = −12
mV; stock SPION dispersion, dispersed in water as the
dispersant) were performed by Unit 9 of the Platform of
Production of Biomaterials and Nanoparticles of the NANBIO-
SIS ICTS, by the Superfícies y Partićulas Nanoestructuradas del
Instituto de Nanociencia de Arago ́n (PI J. Santamariá)
group.44,45 Cos-7, HeLa, and U-87 MG cells were obtained
from ATCC (Manassas, VA). Products for cell culture (media,
phosphate-buffered saline (PBS), glutamine, penicillin−strepto-
mycin solution, Lipofectamine 2000) were obtained from
Gibco, Hyclone, and Invitrogen. SYBR Safe was obtained
from Invitrogen (CA).Magnetic and sterile-storedMSColumns
were purchased from Miltenyi Biotec S.L. (Bergisch Gladbach,
Germany).
Synthesis of pBAE Nanoparticles. Apart from the three
different approaches to form SPION-containing nanoparticles
that are detailed hereafter, pDNA/pBAE nanoparticles (without
SPIONs) were employed as controls in most of the transfection
experiments of this work. First, oligopeptide-modified poly(β-
amino ester)s (OM-pBAEs) were synthesized following a two-
step procedure as described by Segovia et al.20 Then, the
polyplexes (also referred to as NPs) were prepared following
Dosta et al.’s protocol.21 Two polymer backbones, C32 and C6,
were used (see Figure 7), both with Cys + 3Arg as terminal
peptides in both edges. Polymer characterization is presented in
our previous publications.20,21,55 In brief, they were prepared at a
50:1 C32CR3/pDNA or 25:1 C6CR3/pDNA weight ratio by
mixing equal volumes of pDNA at 1 mg mL−1 with the polymer
at 100 mg mL−1 in 25 mM AcONa buffer solution. The pDNA
was added over the polymer solution and mixed by pipetting,
followed by 30 min incubation at 25 °C. For the formation of
discrete structures, this mixture was diluted in a 20-fold volume
of serum-free Dulbecco’s modified Eagle’s medium (DMEM,
4.5 g glucose mL−1 without glutamine, pH = 7.2) prior to each
transfection or in a 10-fold volume of phosphate-buffered saline
(PBS, 1×, pH = 7.4) prior to its physicochemical character-
ization.
SPION-Containing Nanoparticle Synthesis. Three types
of these nanoparticles were formed and tested (see Figure 1A).
All these nanoparticles were freshly prepared in sodium acetate
buffer solution (25 mM, pH = 5.5) and incubated for 30 min at
25 °C. The complexes polymer/DNA/SPIONs were synthe-
Figure 7. Chemical structures of C32CR3 and C6CR3 OM-pBAEs, indicating the C32 and C6 initial polymers reacting with the CR3 peptide.
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tized mixing equal volumes of polymer solution with DNA and/
or SPION solution at different ratios. The synthesis of 50 μL of
S-type C32-CR3/pGFP (50:1) SPION-containing nanopar-
ticles at 5 μg of SPIONs mL−1 is described in detail as an
example. One Eppendorf was prepared with 25 μL of pGFP
DNA solution in sodium acetate buffer 25 mM to get a
concentration of 3 × 10−2 μg of DNA μL−1. Another Eppendorf
was prepared using 0.75 μL of C32-CR3 at 100 mgmL−1 diluted
in sodium acetate buffer 25 mM at 25 μL final volume. The
Eppendorf containing the DNA solution was homogenized with
a micropipette, and its whole volume (25 μL) was added to the
polymer solution Eppendorf, which had just been vortexed for
10 s. This mixture was incubated at 25 °C for 30 min. For the
formation of discrete structures, nanoparticles were then further
diluted in a 10-fold volume of PBS or 20-fold volume of DMEM,
and the necessary volume of SPIONs was added to have a final
concentration of 5 μg of SPIONs mL−1.
Gel Retardation Assays. Gel retardation assays or
electrophoretic mobility shift assays (EMSA) were performed
to confirm the complexation of plasmids with polymers and
SPIONs. T-, S-, and M-type nanoparticles were used. The
polymer to pDNA ratio was fixed at 50:1 (w/w) with 2.5 or 5 μg
mL−1 SPIONs. pBAE/pDNA complexes were freshly prepared
and added to wells of agarose gel (0.8%, SYBR Safe used as
stainer). Samples were run at 80 V for 30 min (Apelex PS 305,
France) and visualized by UV illumination.
Physicochemical Characterization of Nanoparticles.
The particle average hydrodynamic diameter (size) of the
nanoparticles was determined by dynamic light scattering
(DLS) using Zetasizer nano ZS (Malvern Instruments Ltd.,
United Kingdom, 4 mW laser). All the measurements were
performed at 25 °C with 30 s equilibrium time using a laser
wavelength of 633 nm. Correlation functions were collected at a
scattering angle of 173°, and Malvern particle sizing software
(DTS version 5.03) was used to determine the particle
hydrodynamic size. The equipment was set to perform three
measures, each of which consists of 10 cycles of measurements.
The final size value of each sample was equivalent to the mean of
these three measures± standard deviation. The size distribution
was given by the polydispersity index (PDI). The samples to
analyze by DLS were prepared by diluting 100 μL of
nanoparticle solution (in acetate buffer) in 1 mL of final volume
of PBS 1× to simulate the cellular environment. The surface
charge (ζ-potential) of the SPIONs/pBAE/DNA polyplexes
was determined from the electrophoretic mobility by means of
the Smoluchowski equation.64 The ζ-potential measurements
for each sample were performed in triplicates, and every
measurement consisted in 20 cycles of an applied electric field.
For these measures, 800 μL of the previously diluted
nanoparticles was added into a ζ-potential cuvette.
Cell Culture. Cos-7 (ATCC CRL-1651), HeLa (ATCC
CCL-2), and U87MG (ATCCHTB-14) cell lines were cultured
with DMEM (4.5 g glucose mL−1 without glutamine, pH = 7.2)
supplemented with 10% fetal bovine serum (FBS), 1%
penicillin−streptomycin mixture, and the amino acid glutamine
(2 mmol L−1). Cells were grown on incubators at 37 °Cwith 5%
CO2 atmosphere during successive passages and always seeded
24 h before starting any experiment.
In Vitro Cellular Viability and Transfection. Cells were
seeded in 96- and 24-well plates (only for cell sorting
experiments) at a concentration of 4 × 104 cells cm−2.
SPION-containing pBAEs/DNA nanoparticles were prepared
as described above using pGFP. Polyplexes were further diluted
in serum-free DMEM at a final concentration of 1.5 μg pGFP
mL−1. Then, cells were washed with PBS, and for a 96-well plate,
200 μL of the nanoparticle solution was added to each well at a
final pGFP concentration of 0.3 μg per well or 0.1 μgmL−1 in the
case of encapsulated pDNA for Lipofectamine 2000 as the
positive control (optimal concentration recommended by the
manufacturer, lower than that used for our nanoparticles due to
toxicity of Lipofectamine, which does not enable the increase of
the pDNA concentration). Untreated cells were used as negative
controls (results normalized to 100% viability, used to compare
the absorbance of the tested samples). Cells were incubated for 2
h at 37 °C in 5% CO2 atmosphere. Subsequently, transfection
media was removed and fresh supplementedmedia was added to
the cells. After 48 h incubation in the presence of FBS, cell
viability and transfection efficiency were measured.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) was used to quantify cell viability.65 Cells
cultivated in 96-well plates were treated with different
concentrations of SPIONs and incubated for 48 h at 37 °C
and 5%CO2. Then, they were washedwith PBS and incubated in
complete medium supplemented with MTT solution (0.5 mg
mL−1), added at 10% v/v for 3 h at 37 °C and 5% CO2. DMSO
was then added to solubilize the insoluble formazan crystals
formed. Absorbance was measured (Elx808 Biotek Instruments
Ltd) at a wavelength of 550 nm, and values were converted to
percentages of cell viability relative to untreated cells by
normalizing with the absorbance of nontreated cells.
Transfection efficiency was measured by flow cytometry
(FACS; in a BD Fortessa cell analyzer). Forty-eight hours after
transfection, cells were incubated for 5 min with trypsin−
ethylenediaminetetraacetic acid at 37 °C in 5%CO2 atmosphere
and fixed with previously filtered paraformaldehyde (0.22 μm,
2% in PBS). GFP expression was quantified and compared
against a negative control of untreated cells and either a positive
control of Lipofectamine 2000 or a control of pBAE/pGFP
nanoparticles without SPIONs (NPs).
Inductively Coupled Plasma-Optical Emission Spec-
trometry. The iron content of the cells treated with SPIONs or
SPION-containing nanoparticles was determined through an
inductively coupled plasma-optical emission spectrometry
(ICP-OES). Cells were seeded on a 24-well plate, and a
transfection procedure was performed as describe above.
Subsequently, cells were gently washed with PBS to eliminate
the SPIONs that were not internalized. Then, cells were
trypsinized and digested with an oxidative mixture of hydrogen
peroxide (30% v/v) and nitric acid (50% v/v) while heating until
nitrous vapors were observed. The obtained sample was diluted
to a final volume of 10 mL and a nitric acid concentration lower
than 5%. The iron content, in terms of mg of iron per mL, was
calculated by an Optima 2100 DV ICP analyzer (PerkinElmer,
Waltham, Massachusetts). Finally, the amount of iron/cell (in
pg per cell) was determined according to the number of cells
seeded and normalizing the untreated cells (control) as zero pg
of iron/cell.
Magnetic Cell Sorting. HeLa cells, were transfected with
different transfection agents: C6CR3-bsed nanoparticles with-
out SPIONS (NP), S- and M-type nanoparticles at 5μg of
SPIONS mL−1 (S and M), and lipofectamine 2000 (C+). After
that they were trypsinized and fixed and further sorted using MS
columns. For these sorting experiments, 24-well plates were
employed. For each sample, a new column was used. First, the
column was placed in direct contact with strong magnets and it
was equilibrated by loading 1 mL of previously filtered PBS. The
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sample was then loaded, and the eluted fraction (nonmagnetic
cells) was collected. Then, the magnet was removed, the column
was placed on another Falcon tube, and the retained fraction
(magnetic cells) was eluted by adding 2 mL of PBS and pressing
the plunger. Thus, two fractions were obtained from each sorted
sample. Apart from the sorted samples, replicates that were not
sorted were also prepared. Then, these nonsorted samples
together with the magnetic and nonmagnetic fractions of each
sorted sample were centrifuged at 1000 rpm for 5 min. The
supernatant was discarded until only 200 μL of media or PBS
was left, and the pellet was resuspended. This was analyzed by
flow cytometry (FACS) in terms of GFP expression and number
of cells, and it was possible to determine whether the SPIONs
and the DNA/pBAE complexes entered together in the cells or
not.
Statistical Analysis. GraphPad Prism software was used for
the statistical analysis. Two-way ANOVA and t-test were applied
to find out statistical differences between groups or between
each condition as compared to the control group, respectively.
The significance of the difference in the data is *p < 0.05, **p <
0.01, ***p < 0.001, and ****p < 0.0001 regarding controls of
untreated cells (C−) or cells treated with DNA/pBAE
nanoparticles without SPIONs (NPs), depending on the
experiment.
■ CONCLUSIONS
In this work, three types of SPION-containing nanoparticles
with potential as gene delivery carriers have been successfully
developed. Physicochemical characterization and in vitro
screenings have confirmed their suitability as nucleic acid
delivery vectors. Then, this assumption has been evaluated in
different cell cultures, and it has been demonstrated that the
presence of SPIONs on OM-pBAE/pDNA polyplexes has an
enhancer effect on the transfection of both permissive and
reluctant to transfection cell lines. It has been also reported here
a synergic relationship between pBAEs and SPIONs: in the
pBAE/pDNA/SPIONs system, namely, SPIONs help pBAEs in
terms of transfection, whereas pBAEs help SPIONs in the
cellular internalization. Furthermore, the presence of SPIONs in
these polyplexes has allowed not only this unanticipated increase
of cell transfection but also the selective magnetic separation of
genetically modified cells from the ones that do not contain the
foreign DNA. Since the enrichment of the transfected cell
fraction might be crucial for further clinical cell therapy
applications, the results here presented open the door to
SPION-containing nanoparticles as promising tools for cell
therapy approaches.
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